Share this article and save a life!
FDA just unleashed the biggest AI healthcare revolution in history.
On January 6, 2026, FDA announced sweeping deregulation that fundamentally changes how AI reaches patients.
The details are stunning:
📱 General wellness apps and wearables: No longer regulated if they don’t make medical claims
🤖 Clinical decision support AI: Many tools now completely exempt from FDA review
💬 ChatGPT-style health tools: Classified as information sources, not medical devices
🚀 The TEMPO pilot: Digital health companies can treat Medicare patients before full FDA approval
Here’s what this means for healthcare:
The FDA is creating a two-track system. Low-risk AI tools that provide information or support clinical decisions can now reach market immediately. No 510(k). No lengthy reviews. Just launch.
Meanwhile, diagnostic and treatment AI still faces oversight, but through streamlined pathways that emphasize real-world outcomes over theoretical risks.
This shift recognizes a critical reality: The traditional medical device framework was strangling innovation. While FDA spent months reviewing step counters, patients couldn’t access potentially life-saving AI tools.
But here’s the tension:
We’re essentially running a massive real-world experiment. Millions will use unregulated AI health tools. Some will benefit tremendously. Others may face risks we haven’t anticipated.
The market, not regulators, will now determine which AI tools succeed. Patient outcomes and provider adoption will separate valuable innovations from digital snake oil.
For health systems, this changes everything. You can now deploy AI decision support without regulatory barriers. Your biggest challenge shifts from compliance to validation: Which tools actually improve care?
For startups, the gates are open. But with freedom comes responsibility. Without FDA’s seal of approval, you’ll need robust evidence and stellar outcomes to earn trust.
The most fascinating part? FDA is tying reimbursement to outcomes through the ACCESS model. Get paid for results, not just clearance. That’s revolutionary thinking from a traditionally conservative agency.
We’re witnessing healthcare’s iPhone moment. When Apple launched the App Store, they didn’t regulate every app. They created a platform and let innovation flourish.
FDA just did the same for healthcare AI.
The question isn’t whether this will transform medicine. It’s whether our health systems, providers, and patients are ready for the tsunami of AI tools heading their way.
♻️ Repost if healthcare AI should prioritize innovation over regulation.
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
